China's Innovent Biologics Emerges As Immuno-Oncology Competitor With Sintilimab Approval

 
• By John Davis
  
Shanghai
China's biotech companies are an emerging force in immuno-oncology R&D • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer